Brief: Amneal Announces BLA Submission Of Biosimilar Candidate To Xolair® (Omalizumab)
26/09/2025 13:05
Sept 26 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL ANNOUNCES BLA SUBMISSION OF BIOSIMILAR CANDIDATE TO XOLAIR® (OMALIZUMAB) AMNEAL PHARMACEUTICALS INC - CO EXPECTS $22.5 MILLION RESEARCH AND DEVELOPMENT CHARGE IN QTRLY 2025 Source text: ID:nGNX67cWml Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
U.S. STOCKS ON THE MOVE-Chipotle Mexican Grill, J.B. Hunt, ABM Industries
U.S. STOCKS ON THE MOVE-G-III Apparel, Amneal Pharmaceuticals, BioCardia
U.S. STOCKS ON THE MOVE-Lululemon, Cooper Companies, Cypherpunk Technologies
Amneal Pharma up after Parkinson’s drug shows benefit in late-stage study